文献速递肝病

血浆胱抑素C可预测急性失代偿期肝硬化患者的肾功能障碍、慢加急性肝衰竭和死亡

Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis.
PubMed 文献 · Hepatology · 2017-08-26

该研究在CANONIC队列429例因肝硬化急性失代偿住院患者中检测血浆胱抑素C和中性粒细胞明胶酶相关脂质运载蛋白水平并随访90天。基线胱抑素C可预测肾功能障碍、肝肾综合征和慢加急性肝衰竭,且为死亡的独立预测因素;NGAL仅与短期死亡相关,不能预测上述并发症。

要点

  • 基线胱抑素C可预测肾功能障碍(OR 9.4)、肝肾综合征(OR 4.2)和慢加急性肝衰竭(OR 5.9)。
  • 胱抑素C(HR 3.1)和NGAL(HR 1.9)均与90天死亡相关,但NGAL不能预测肾功能障碍、肝肾综合征和慢加急性肝衰竭。
  • 第3天胱抑素C并不优于基线胱抑素C的预测价值。

核心结论

  • 基线胱抑素C是急性失代偿期肝硬化患者肾功能障碍、肝肾综合征和慢加急性肝衰竭的生物标志物,也是死亡的独立预测因素;第3天测定胱抑素C未提供额外获益;NGAL虽与短期死亡相关,但不能预测肾功能障碍、肝肾综合征和慢加急性肝衰竭的发生。
  • 作者认为基线胱抑素C可能有助于更早识别高危患者并改善临床管理。

研究设计与样本

  • 在EASL-CLIF慢加急性肝衰竭研究(CANONIC)中,测定429例因肝硬化急性失代偿住院患者的血浆胱抑素C和NGAL水平,并随访90天。

主要发现

  • 入组时无肾功能障碍或慢加急性肝衰竭但随后发生其中任一情况的患者,其基线胱抑素C和NGAL浓度显著高于未发生者。
  • 胱抑素C可预测肾功能障碍(比值比9.4,95%CI 1.8-49.7)、肝肾综合征(比值比4.2,95%CI 1.2-14.8)和慢加急性肝衰竭(比值比5.9,95%CI 1.3-25.9),NGAL则不能。
  • 第3天胱抑素C的预测价值并不优于基线胱抑素C。
  • 胱抑素C和NGAL均可预测90天死亡,胱抑素C的风险比为3.1(95%CI 2.1-4.7),NGAL的风险比为1.9(95%CI 1.5-2.4)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The development of acute-on-chronic liver failure (ACLF) in patients with liver cirrhosis is associated with high mortality rates. Renal failure is the most significant organ dysfunction that occurs in ACLF. So far there are no biomarkers predicting ACLF. We investigated whether cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL) can predict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF, and mortality. We determined the plasma levels of CysC and NGAL in 429 patients hospitalized for acute decompensation of cirrhosis in the EASL-CLIF Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC) study. The patients were followed for 90 days. Patients without RD or ACLF at inclusion but with development of either had significantly higher baseline concentrations of CysC and NGAL compared to patients without. CysC, but not NGAL, was found to be predictive of RD (odds ratio, 9.4; 95% confidence interval [CI], 1.8-49.7), HRS (odds ratio, 4.2; 95% CI, 1.2-14.8), and ACLF (odds ratio, 5.9; 95% CI, 1.3-25.9). CysC at day 3 was not found to be a better predictor than baseline CysC. CysC and NGAL were both predictive of 90-day mortality, with hazard ratios for CysC of 3.1 (95% CI, 2.1-4.7) and for NGAL of 1.9 (95% CI, 1.5-2.4). CONCLUSION: Baseline CysC is a biomarker of RD, HRS, and ACLF and an independent predictor of mortality in patients with acutely decompensated liver cirrhosis, though determining CysC at day 3 did not provide any benefit; while NGAL is also associated with short-term mortality, it fails to predict development of RD, HRS, and ACLF. Baseline CysC may help to identify patients at risk earlier and improve clinical management. (Hepatology 2017;66:1232-1241).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Markwardt D, Holdt L, Steib C, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology. 2017. PMID: 28545169. doi:10.1002/hep.29290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。